The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 483.76% and ...
Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...
The FDA rejected sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control in adults with type 1 ...
Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...
StudyFinds' Dr. Faith Colemans explains why shopping for weight loss drugs online may save you money but endanger your health ...
The third ‘Downton Abbey’ film honors the late Dame Maggie Smith and her iconic portrayal of Violet Crawley. The drug is ...
Following billionaire investors isn't as difficult as you might imagine thanks to quarterly reporting required by the ...
During FDA-declared shortages, pharmacists can legally make compounded versions of brand-name medications. But drugmakers and ...
The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.
A sign with the company logo stands in front of the Eli Lilly and Company headquarters campus in Indianapolis, Indiana, on March 17, 2024. New study data has solidified the club's position Eli Lillyis ...